Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

Invivyd reports clinical efficacy data from CANOPY phase 3 trial of pemivibart: Waltham, Massachusetts Friday, November 15, 2024, 18:00 Hrs [IST] Invivyd, Inc, a biopharmaceutical ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

The first will explore its use in combination with a PD-1 monoclonal antibody in the treatment of perioperative urothelial carcinoma, while the second will investigate its combination with other ...

Invivyd (IVVD) announces that The New England Journal of Medicine, NEJM, has published a peer-reviewed Letter to the Editor describing the ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

Continuous research has led to new drug developments, particularly disease-modifying therapies (DMTs) that slow MS ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the Union World Conference on ...

Advances in clinical development keep the hope alive of having new drugs in the not-so-distant future to complement the ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...